Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported a series of insider trades in the company’s common stock. On March 2, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share, receiving 9,500 shares of common stock.
That same day, she conducted multiple open‑market sales totaling 9,500 shares of common stock, at reported weighted‑average prices generally between about $507 and $525 per share across numerous trades. The Form 4 notes these transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026.
The filing also reports indirect holdings of common stock through a spouse and various family trusts, where the reporting person or her immediate family share or hold investment power and are beneficiaries.
Morgan Stanley Smith Barney LLC Executive Financial Services reported a proposed sale of 50 shares of common stock (restricted stock) of United Therapeutics Corporation (symbol UTHR) under Form 144.
The filing lists multiple recent small dispositions of 50 shares each on 12/11/2025, 12/23/2025, 01/06/2026, 01/20/2026, 02/03/2026, and 02/17/2026, with per‑trade amounts shown in the excerpt.
Martine Rothblatt filed a Form 144 notice to sell 209,000 common shares of UTHR on 03/02/2026 via exercise of stock options through Morgan Stanley Smith Barney LLC, with payment in cash. The filing also lists multiple prior open-market dispositions in December 2025, mostly 4,000-share lots and one 2,000 lot.
UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of common stock. She sold 200 shares on February 27, 2026 at an average price of $509.55 per share under a pre-arranged Rule 10b5-1 trading plan entered into on November 24, 2025. After this transaction, she directly owns 4,845 common shares.
United Therapeutics reported that its pivotal phase 3 ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension met its primary goal. Ralinepag reduced the risk of a clinical worsening event by 55% versus placebo and increased the odds of clinical improvement by 47% through Week 28.
The once-daily oral prostacyclin showed statistically significant benefits on six-minute walk distance and NT-proBNP, with no new safety signals observed. The company plans to submit a New Drug Application for ralinepag to the FDA by the second half of 2026 and is hosting a webcast to discuss the results.
United Therapeutics Corporation executive vice president and general counsel Paul A. Mahon reported equity awards tied to multi-year performance goals. He acquired 49,860 performance-based stock options and two tranches of performance-based restricted stock units covering 7,796 and 8,895 units, all at a grant price of $0 per unit.
The options were earned based on average cash profit margin for 2023-2025, while the restricted stock units were earned based on average revenue growth and clinical development performance over 2023-2025. All reported awards will vest on March 15, 2026, and each restricted stock unit converts into one share of common stock after vesting.
ROTHBLATT MARTINE A reported acquisition or exercise transactions in this Form 4 filing.
UNITED THERAPEUTICS Corp reported new performance-based equity awards for Chairperson & CEO Martine A. Rothblatt. She was credited with 207,720 stock options and two blocks of performance-based restricted stock units covering 32,499 and 37,080 units.
The options are tied to average cash profit margin during 2023–2025, while the RSUs are tied to average revenue growth and clinical development performance over the same 2023–2025 period. Performance outcomes were determined in early 2026, and all earned options and RSUs are scheduled to vest on March 15, 2026, with each RSU delivering one common share at vesting.
UNITED THERAPEUTICS Corp reported that President and COO Michael Benkowitz acquired equity awards tied to multi‑year performance goals. On March 15, 2023 he was granted 99,720 performance-based stock options earned from a three-year cash profit margin target for 2023-2025, which will vest on March 15, 2026.
He was also granted 15,592 performance-based restricted stock units tied to average revenue growth for 2023-2025 and 17,790 performance-based restricted stock units tied to clinical development performance for 2023-2025; both awards were earned based on performance and will vest on March 15, 2026. Each restricted stock unit converts into one share of common stock after vesting.
United Therapeutics reported that CFO and Treasurer James Edgemond acquired new equity awards made up of stock options and performance-based restricted stock units. He received 58,170 stock options and two tranches of restricted stock units totaling 9,098 and 10,380 units.
The stock options are tied to a three-year performance condition based on average cash profit margin during 2023-2025, with performance determined in February 2026. One restricted stock unit grant is tied to average revenue growth during 2023-2025, with performance also determined in February 2026, while the other is tied to clinical development performance during 2023-2025, determined in January 2026.
All earned awards will vest on March 15, 2026. Each restricted stock unit gives the right to receive one share of United Therapeutics common stock after vesting, and the units do not have an expiration date.